Johansson B, Georgiev V, Parkinson F E, Fredholm B B
Department of Pharmacology, Karolinska Institutet, Stockholm, Sweden.
Eur J Pharmacol. 1993 Oct 15;247(2):103-10. doi: 10.1016/0922-4106(93)90066-i.
The binding of the reportedly A2A selective agonist CGS 21680 (2-[p-(2-carboxyethyl)phenylethylamino]-5'N-ethylcarboxamidoadenos ine) to cortex and striatum was examined in parallel using quantitative receptor autoradiography. [3H]CGS 21680 bound to a single site in rat striatum with KD 2.3 nM and Bmax 320 fmol/mg grey matter. In addition [3H]CGS 21680 bound to a single site in the cerebral cortex with KD 47 nM and Bmax 100 fmol/mg grey matter. In cat cortex [3H]CGS 21680 (2 nM) binding was strong and particularly evident in the most superficial layers. The potency order for inhibition of 2 nM [3H]CGS 21680 binding to rat striatum was NECA (5'-N-ethylcarboxamidoadenosine; IC50 9.0 nM) > 2-CADO (2-chloroadenosine; 87 nM) > R-PIA (N6-(R)-phenylisopropyladenosine; 110 nM). The potency order for inhibition of 2 nM [3H]CGS 21680 binding to rat cortex was NECA (3.0 nM) > 2-CADO (14 nM) > or = R-PIA (16 nM). Gpp(NH)p (5'-guanylyl imidodiphosphate) inhibited [3H]CGS 21680 binding to both cortex and striatum, but more potently in cortex (IC50 100 nM vs. 470 nM). The present results show that there is a cortical binding site for [3H]CGS 21680 which appears to be different from the the striatal A2A receptor, the A2B receptor and the A1 receptor.
使用定量受体放射自显影技术,平行检测了据报道为A2A选择性激动剂的CGS 21680(2-[对-(2-羧乙基)苯乙氨基]-5'-N-乙基羧酰胺基腺苷)与皮质和纹状体的结合情况。[3H]CGS 21680与大鼠纹状体中的单一位点结合,解离常数(KD)为2.3 nM,最大结合容量(Bmax)为320 fmol/mg灰质。此外,[3H]CGS 21680与大脑皮质中的单一位点结合,KD为47 nM,Bmax为100 fmol/mg灰质。在猫的皮质中,[3H]CGS 21680(2 nM)的结合很强,在最表层尤为明显。抑制2 nM [3H]CGS 21680与大鼠纹状体结合的效力顺序为NECA(5'-N-乙基羧酰胺基腺苷;半数抑制浓度(IC50)为9.0 nM)> 2-CADO(2-氯腺苷;87 nM)> R-PIA(N6-(R)-苯异丙基腺苷;110 nM)。抑制2 nM [3H]CGS 21680与大鼠皮质结合的效力顺序为NECA(3.0 nM)> 2-CADO(14 nM)>或 = R-PIA(16 nM)。鸟苷-5'-O-(3-硫代三磷酸)(Gpp(NH)p)抑制[3H]CGS 21680与皮质和纹状体的结合,但对皮质的抑制作用更强(IC50为100 nM对470 nM)。目前的结果表明,存在一个[3H]CGS 21680的皮质结合位点,它似乎与纹状体A2A受体、A2B受体和A1受体不同。